IAVI

Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Press Releases

Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC

May 16, 2023

TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID-19, and sickens more than 10 million people annually. A new TB vaccine is needed to reach global END TB goals. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an…

Read more

Press Releases

IAVI announces renewed support from the Danish government for its HIV prevention program

March 24, 2023

Denmark, represented by the Danish Ministry of Foreign Affairs is committed to contribute a total of DKK 20 million (US$3 million) from 2022-2025.

Read more

Press Releases

IAVI and BARDA expand partnership to advance IAVI’s filovirus vaccine candidates

March 1, 2023

Funding will allow for additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus and Sudan ebolavirus.

Read more

Press Releases

The Netherlands renews their support to IAVI for the development of new HIV prevention technologies

February 22, 2023

The Ministry will award IAVI €21 million over the next five years as part of the Product Development Partnership IV Fund.

Read more

Press Releases

Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach

December 2, 2022

Scripps Research, IAVI, Fred Hutch, VRC and other collaborators publish study data in Science, helping validate novel vaccination strategy.

Read more

Press Releases

IAVI to accelerate promising investigational Sudan ebolavirus vaccine development for potential outbreak research and response

October 25, 2022

Merck will provide the investigational vaccine based on a proven platform technology.

Read more

Press Releases

IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate

August 31, 2022

The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity.

Read more

Press Releases

Japan reiterates commitment to HIV vaccine development with a $10.5 million contribution to IAVI

August 29, 2022

NEW YORK, NY — AUGUST 29, 2022 — The Government of Japan announced at the occasion of the Eighth Tokyo International Conference on African Development (TICAD8) held in Tunisia on August 27 and 28, 2022, its commitment to contribute US$10.5 million to IAVI’s VSV-HIV vaccine development program over the next five years. This funding will…

Read more